ICI increases anti-tumor immunity by blocking intrinsic checkpoints that have an inhibitory role in regulating T cell responses, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1). This evidence concerns the gene CTLA4 and neoplasm.